ProTransit NanoTherapy
2013
FOUNDED
PRIVATE
STATUS
1-10
EMPLOYEES
Grant
LATEST DEAL TYPE
(Announced)
4
INVESTORS
Description
Provider of a proprietary nanoparticle delivery system intended to treat conditions caused or related to free radical formation. The company's initial system is for skincare, where the application helps to reduce cellular and DNA damage caused by UV exposure, as well as helps to treat acute spinal cord injury, enabling physicians to treat their patients in an enhanced way.
Website
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Biotechnology
Other Industries
Other Devices and Supplies
Drug Discovery
Other Healthcare Services
Primary Office
- 16514 L Street
- Omaha, NE 68135
- United States
+1 (608) 000-0000
Request full access to PitchBook
You’re viewing a free company profile from the PitchBook Platform. To explore ProTransit NanoTherapy’s full profile, request a free trial.
ProTransit NanoTherapy Valuation and Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 3. Grant | 13-Aug-2018 | 00000 | Announced | Pre-Clinical Trials | ||
| 2. Grant | 08-Mar-2017 | 00.00 | 00000 | Completed | Pre-Clinical Trials | |
| 1. Early Stage VC (Series A) | 21-Nov-2014 | $250K | $250K | Completed | Pre-Clinical Trials |
ProTransit NanoTherapy Investors (4)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Board Seat |
Contact Info |
|---|---|---|---|---|---|---|
| United States Department of Defense | Government | 000 0000 | 000000 0 | |||
| Invest Nebraska | Venture Capital | Minority | 000 0000 | 000000 0 | ||
| Notox Technologies | Corporate Venture Capital | Minority | 000 0000 | 000000 0 | ||
| National Institutes of Health | Government | 000 0000 | 000000 0 |